{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:05:36Z","timestamp":1779296736809,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>In addition to monoclonal antibodies against proprotein convertase subtilisin-kexin type 9 (PCSK9), vaccines against PCSK9 and smaller molecule inhibitors as well as RNA inhibitors of PCSK9 production have been created. The monoclonal antibodies against PCSK9 and the PCSK9 RNA inhibitors can reduce low-density lipoproteins (LDLs) by over 50%, non-high-density lipoprotein (HDL) cholesterol and triglycerides, and increasing HDL. Although effective in several homozygous familial hypercholesterolemia patient types, PCSK9 inhibitors does not work in all patient types. Outcome trials show no effects on mortality but do show reductions in atherosclerotic events such as myocardial infarctions, strokes, and need for coronary revascularization. PCSK9 inhibitors have a very attractive safety profile with no significant elevations in measures of muscle or liver damage. The current and more advanced experimental agents all require subcutaneous dosing, and injection site reactions are among the most common adverse events. Therapy for the Food and Drug Administration\u00a0(FDA) approved agents is markedly expensive, and this is the primary barrier to utilization. However, it is possible to identify patients with a number needed to treat to prevent an atherosclerotic event low enough to render it cost-effective and one such factor is whether or not you require a 50% reduction in LDL in order to achieve your LDL goal.<\/jats:p>","DOI":"10.1177\/1074248418769040","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T21:42:14Z","timestamp":1523569334000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-4893","authenticated-orcid":false,"given":"C. Michael","family":"White","sequence":"first","affiliation":[{"name":"UCONN and Hartford Hospital, University of Connecticut School of Pharmacy, Storrs"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"bibr1-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015608487"},{"key":"bibr2-1074248418769040","unstructured":"Repatha: Package Insert and label information. http:\/\/pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.pdf. Accessed March 27 ,2018. Updated December 2017."},{"key":"bibr3-1074248418769040","unstructured":"Praluent: Package insert and label information. Sanofi-Aventis, LLC. http:\/\/druginserts.com\/lib\/rx\/meds\/praluent\/. Accessed March 27, 2018. Updated January, 2018."},{"key":"bibr4-1074248418769040","unstructured":"IAD Week. Regeneron, Sanofi Price Praluent at $14,560\/Yr\u2014market talk. http:\/\/iadweek.me\/2015\/07\/24\/regeneron-sanofi-price-praluent-at-14560yr-market-talk\/. Accessed August 12, 2015."},{"key":"bibr5-1074248418769040","unstructured":"Pfizer press release. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. 11, 2017. Available at: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accessed April 16, 2018."},{"key":"bibr6-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701488"},{"key":"bibr7-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2014.05.011"},{"key":"bibr8-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283613a3d"},{"key":"bibr9-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1111\/j.0009-9163.2004.0238.x"},{"key":"bibr10-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.02.044"},{"key":"bibr11-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"bibr12-1074248418769040","unstructured":"Dorey E. Cholesterol-busting PCSK9 drugs. Pharmaceut J 2017;1 6. https:\/\/www.pharmaceutical-journal.com\/news-and-analysis\/features\/pcsk9-inhibitors-the-next-cholesterol-lowering-blockbusters\/20068181.article. Accessed March 27, 2018."},{"key":"bibr13-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"bibr14-1074248418769040","unstructured":"Stein EA, Kasichayanula S, Turner T, LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study 2017;3 17. https:\/\/www.medpace.com\/wp-content\/uploads\/2017\/06\/BMS-Adnectin-ACC-Final.pdf. Accessed March 27, 2018."},{"key":"bibr15-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"bibr16-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"bibr17-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"bibr18-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006910"},{"key":"bibr19-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2012.10.021"},{"key":"bibr20-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.060"},{"key":"bibr21-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318925"},{"key":"bibr22-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"bibr23-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13114"},{"key":"bibr24-1074248418769040","unstructured":"Regeneron\/Sanofi Media Release: Regeneron and Sanofi Announce Praluent (Alirocumab) cardiovascular outcomes trial will continue as planned following interim analysis 2016;11 17. http:\/\/investor.regeneron.com\/releasedetail.cfm?releaseid=999878. Accessed March 27, 2018."},{"key":"bibr25-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"bibr26-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"bibr27-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"key":"bibr28-1074248418769040","first-page":"64","volume":"2","author":"White CM","year":"2014","journal-title":"Drug Topics"},{"key":"bibr29-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"bibr30-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.928"},{"key":"bibr31-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.01.001"},{"key":"bibr32-1074248418769040","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317717346"},{"key":"bibr33-1074248418769040","unstructured":"Steg PG. American College of Cardiology Annual Meeting; For the ODYSSSEY Outcomes Investigators. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab\u2014ODYSSEY Outcomes 2018; 3 11. Available at: http:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2018\/03\/09\/08\/02\/odyssey-outcomes. Accessed March 13, 2018."}],"updated-by":[{"DOI":"10.1177\/1074248418777807","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T00:00:00Z","timestamp":1527465600000}}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418769040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248418769040","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418769040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:45Z","timestamp":1777394565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248418769040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1177\/1074248418769040"],"URL":"https:\/\/doi.org\/10.1177\/1074248418769040","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]}}}